Pirarreumol "B"
Brand names,
Pirarreumol "B"
Analogs
Pirarreumol "B"
Brand Names Mixture
- Alka Phenyl Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)
- Alka Phenylbutazone Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)
- Phenylone Plus Tab (Aluminum Hydroxide + Magnesium Trisilicate + Phenylbutazone)
Pirarreumol "B"
Chemical_Formula
C19H20N2O2
Pirarreumol "B"
RX_link
No information avaliable
Pirarreumol "B"
fda sheet
Pirarreumol "B"
msds (material safety sheet)
Pirarreumol "B"
Synthesis Reference
Ullmann's Encyklopaedie der Technischen Chemie 13, 298 (1962)
Pirarreumol "B"
Molecular Weight
308.374 g/mol
Pirarreumol "B"
Melting Point
105 oC
Pirarreumol "B"
H2O Solubility
47.5 mg/L
Pirarreumol "B"
State
Solid
Pirarreumol "B"
LogP
4.214
Pirarreumol "B"
Dosage Forms
Bolus; Liquid; Paste; Powder; Solution; Tablet
Pirarreumol "B"
Indication
For the treatment of backache and ankylosing spondylitis
Pirarreumol "B"
Pharmacology
Phenylbutazone is a synthetic, pyrazolone derivative. It is a nonhormonal anti-inflammatory, antipyretic compound useful in the management of inflammatory conditions. The apparent analgesic effect is probably related mainly to the compound's anti-inflammatory properties and arise from its ability to reduce production of prostaglandin H and prostacyclin. Prostaglandins act on a variety of cells such as vascular smooth muscle cells causing constriction or dilation, on platelets causing aggregation or disaggregation and on spinal neurons causing pain. Prostacylcin causes vascular constriction platelet disaggregation
Pirarreumol "B"
Absorption
No information avaliable
Pirarreumol "B"
side effects and Toxicity
Oral, LD50 = 238 mg/kg (mouse); Oral, LD50 = 781 mg/kg (rabbit); Oral, LD50 = 245 mg/kg (rat); Oral, LD50 = 375 mg/kg (rat)
Pirarreumol "B"
Patient Information
No information avaliable
Pirarreumol "B"
Organisms Affected
Humans and other mammals